Incidence of hepatitis C recurrence after kidney transplantation and response to direct-acting antiviral therapy
A multi center study
Keywords:
topical antiviral agents, sustained antiviral therapy response, hepatitis CAbstract
Aim: The purpose of this study is to investigate the efficacy and graft survival of direct antiviral agents in Hepatitis C-positive renal transplant recipients. Design: A Multi center study. Duration & place of study: From February 2020 to February 2021, a cohort of Hepatitis C positive Renal Transplant Recipients will participate in a study at the Saidu teachnig hospital Swat and ikd peshawar. Methodology: the study conducted in STH and IKD peshawar Patients with hepatitis C who have received a kidney transplant will be chosen if they meet the inclusion and exclusion criteria, and then they will be followed for three months after starting the direct acting antiviral (DAA) treatment. Result: With a mean age of 35.01±11.6 years, the study's 100 participants were evenly split between sexes (62% male). The treatment for HCV was a [100%] success. Throughout the course of therapy (ranging from 6-12 weeks), there was no discernible shift in the mean values of total bilirubin, haemoglobin, platelet count, serum creatinine, or estimated glomerular filtration rate. ALP levels decreased considerably across all time points of follow-up, whereas ALT and AST levels decreased rapidly over the first 4 weeks and thereafter stabilised.
Downloads
References
Alpers C, Bloom RD, Fabrizi F, Izopet J, Jadoul M, Lindley E, Martin P, Morales JM, Natov S, Pol S, Reddy KR. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease: introduction. Kidney International. 2008;73(suppl. 109):S6-99.
Calanca LN, Fehr T, Jochum W, Fischer-Vetter J, Müllhaupt B, Wüthrich RP, Ambühl PM. Combination therapy with ribavirin and amantadine in renal transplant patients with chronic hepatitis C virus infection is not superior to ribavirin alone. Journal of clinical virology. 2007 May 1;39(1):54-8.
Charlton M, Gane E, Manns MP, Brown Jr RS, Curry MP, Kwo PY, Fontana RJ, Gilroy R, Teperman L, Muir AJ, McHutchison JG. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015 Jan 1;148(1):108-17.
Delabaudière C, Lavayssière L, Dörr G, Muscari F, Danjoux M, Sallusto F, Peron JM, Bureau C, Rostaing L, Izopet J, Kamar N. Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney–liver transplantation. Transplant International. 2015 Feb;28(2):255-8.
Fabrizi F, Messa P, Martin P. Update to hepatitis C review. Kidney International. 2014 May 1;85(5):1238-9.
Forns X, Charlton M, Denning J, McHutchison JG, Symonds WT, Brainard D, Brandt‐ Sarif T, Chang P, Kivett V, Castells L, Prieto M. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology. 2015 May;61(5):1485-94.
Forns X, Prieto M, Charlton M, McHutchison JG, Symonds WT, Denning J, Brandt-Sarif T, Chang P, Kivett V, Fontana RJ, Baumert TF. O62 sofosbuvir compassionate use program for patients with severe recurrent hepatitis c including fibrosing cholestatic hepatitisfollowing liver transplantation. Journal of Hepatology. 2014 Apr 1;60(1):S26.
Initial treatment of chronic hepatitis C: a randomised trial. The Lancet. 2001 Sep 22;358(9286):958-65.
Jha R, Fatima R, Lakhtakia S, Jha A, Srikant P, Narayan G. Ledipasvirand sofosbuvir for treatment of post-renal transplant hepatitis C infection: a case report with review of literature. Indian journal of nephrology. 2016 May;26(3):216.
Kamar N, Marion O, Rostaing L, Cointault O, Ribes D, Lavayssière L, Esposito L, Del Bello A, Métivier S, Barange K, Izopet J. Efficacy and safety of sofosbuvir‐ based antiviral therapy to treat hepatitis C virus infection after kidney transplantation. American Journal of Transplantation. 2016 May;16(5):1474-9.
Kamar N, Rostaing L, Sandres-Saune K, Ribes D, Durand D, Izopet J. Amantadine therapy in renal transplant patients with hepatitis C virus infection. Journal of clinical virology. 2004 May 1;30(1):110- 4.
Kamar N, Sandres-Saune K, Selves J, Ribes D, Cointault O, Durand D, Izopet J, Rostaing L. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. American journal of kidney diseases. 2003 Jul 1;42(1):184-92.
Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. New England Journal of Medicine. 2014 May 15;370(20):1879-88.
Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. The Lancet. 2014 Nov 15;384(9956):1756-65.
Lubetzky M, Chun S, Joelson A, Coco M, Kamal L, Ajaimy M, Gaglio P, Akalin E, De Boccardo G. Safety and efficacy of treatment of hepatitis C in kidney transplant recipients with directly acting antiviral agents. Transplantation. 2017 Jul 1;101(7):1704-10.
MORALES JM, Campistol JM. Transplantation in the patient with hepatitis C. Journal of the American Society of Nephrology. 2000 Jul 1;11(7):1343-53.
Pellicelli AM, Montalbano M, Lionetti R, Durand C, Ferenci P, D’Offizi G, Knop V, Telese A, Lenci I, Andreoli A, Zeuzem S. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Digestive and Liver Disease. 2014 Oct 1;46(10):923-7.
Sawinski D, Bloom RD. Novel hepatitis C treatment and the impact on kidney transplantation. Transplantation. 2015 Dec 1;99(12):2458-66.
Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. New England Journal of Medicine. 2014 Jan 16;370(3):211-21.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
